You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 126 No. 12, December 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  STUDIES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (11)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Primary Dapsone-Resistant Hansen's Disease in California

Experience With Over 100 Mycobacterium leprae Isolates

Robert H. Gelber, MD; Thomas H. Rea, MD; Lydia P. Murray; Patricia Siu; Mabel Tsang; Sally R. Byrd, MD

Arch Dermatol. 1990;126(12):1584-1586.


Abstract

• We found that in the years 1978 through 1981 only one of 54 previously untreated patients with Hansen's disease was found to harbor dapsone-resistant Mycobacterium leprae. That single strain was only partially resistant, ie, it was resistant to 0.0001% dapsone in a mouse diet but not to higher concentrations. During the years 1983 through 1988, Mleprae from 47 previously untreated patients presenting to clinics in San Francisco, Calif, and Los Angeles, Calif, grew in mice. None of these strains was found to be dapsone resistant. Thus, from 1978 through 1988 only one of 101 M leprae isolates obtained from skin biopsy specimens from patients with leprosy was found to be resistant to dapsone. We have concluded that primary dapsone resistance still does not appear to be a significant problem in California. Owing to the fact that our single resistant case and those reported from international sources are, in general, partially resistant, the potential importance of partial dapsone resistance is discussed.

(Arch Dermatol. 1990;126:1584-1585)



Author Affiliations

From the Kuzell Institute for Arthritis and Infectious Diseases, Medical Research Institute of San Francisco (Calif), and Gillis W. Long Hansen's Disease Center, Carville, La (Drs Gelber and Byrd and Mss Murray, Siu, and Tsang); and Section of Dermatology, University of Southern California School of Medicine, Los Angeles (Dr Rea).


Footnotes

Accepted for publication August 20, 1990.

Reprint requests to Kuzell Institute for Arthritis and Infectious Diseases, 2200 Webster St, San Francisco, CA 94115-1896 (Dr Gelber).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Comparative Clinical Trial in Multibacillary Leprosy with Long-Term Relapse Rates of Four Different Multidrug Regimens
Fajardo et al.
Am J Trop Med Hyg 2009;81:330-334.
ABSTRACT | FULL TEXT  

The Face of Leprosy in the United States Today
Jacobson and Hansen
Arch Dermatol 1990;126:1627-1630.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.